Formulation of Biologics Including Biopharmaceutical Considerations

9Citations
Citations of this article
29Readers
Mendeley users who have this article in their library.
Get full text

Abstract

This chapter describes the various issues a formulator of biologics faces when turning an active pharmaceutical ingredient (API) into a biopharmaceutical product that can be administered to a patient. A well-equipped analytical lab to characterize chemical and physical characteristics of the protein in the formulation process is a first requirement. Then, the proper excipients and conditions (e.g., freeze-dried or not; refrigerated or not) to achieve an acceptable shelf-life of the formulated protein can be selected. Throughout this process one should consider the specific requirements linked to the desired route of administration, e.g., dose, volume, primary container. Alternative routes of administration are briefly discussed and their limitations listed.

Cite

CITATION STYLE

APA

Crommelin, D. J. A., Hawe, A., & Jiskoot, W. (2019). Formulation of Biologics Including Biopharmaceutical Considerations. In Pharmaceutical Biotechnology: Fundamentals and Applications (pp. 83–103). Springer International Publishing. https://doi.org/10.1007/978-3-030-00710-2_5

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free